XORTX Therapeutics (XRTX) Other Non Operating Income (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Other Non Operating Income came in at $6190.0 in Q1 2026, up 1609.94% YoY from $362.0 in Q1 2025, and up 615.61% on a QoQ basis from $865.0 in Q4 2025.
XORTX Therapeutics (XRTX) Other Non Operating Income (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Other Non Operating Income data on file, last reported at $6190.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 1609.94% year-over-year to $6190.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1501.0 (up 102.5% YoY) and the FY2025 annual result came in at -$4327.0, up 94.07% from the prior year.
- Other Non Operating Income grew to $6190.0 in Q1 2026, from $865.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $143318.9 in Q4 2022 to a low of -$389399.0 in Q3 2022.
- A 5-year average of -$40432.3 and a median of -$3668.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income slumped 51066.97% — and 2026, when it jumped 1609.94%.
- Tracing XRTX's Other Non Operating Income over 5 years: stood at $143318.9 in 2022, then sank by 95.07% to $7062.6 in 2023, then sank by 911.83% to -$57336.0 in 2024, then surged by 101.51% to $865.0 in 2025, then jumped by 615.61% to $6190.0 in 2026.
- The last three Other Non Operating Income figures came in at $6190.0 (Q1 2026), $865.0 (Q4 2025), and -$16473.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,190.00 |
| Dec 31, 2025 | 865.00 |
| Sep 30, 2025 | -16,473.00 |
| Jun 30, 2025 | 10,919.00 |
| Mar 31, 2025 | 362.00 |
| Dec 31, 2024 | -57,336.00 |
| Sep 30, 2024 | 14,715.00 |
| Jun 30, 2024 | -17,744.00 |
| Mar 31, 2024 | -12,644.00 |
| Dec 31, 2023 | 7,062.56 |
| Sep 30, 2023 | -3,668.00 |
| Jun 30, 2023 | 2,601.12 |
| Mar 31, 2023 | -6,255.61 |
| Dec 31, 2022 | 143,318.93 |
| Sep 30, 2022 | -389,398.98 |
| Jun 30, 2022 | -214,022.25 |
| Mar 31, 2022 | -155,840.87 |
| Dec 31, 2021 | -275,062.31 |
| Sep 30, 2021 | -9,725.16 |
| Jun 30, 2021 | 7,336.00 |